• Explore /
  • Poster
  • / Phase II multi-center study of sintilimab in combination with axitinib in patients with advanced fumarate hydratase-deficient renal cell carcinoma.

Phase II multi-center study of sintilimab in combination with axitinib in patients with advanced fumarate hydratase-deficient renal cell carcinoma.

Abstract Poster

Authors

null

Xingming Zhang

Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China

Xingming Zhang , Haoyang Liu , Yaowen Zhang , Junjie Zhao , Yuntian Chen , Guangxi Sun , Xinan Sheng , Yongquan Wang , Kan Gong , Xiaodong Liu , Rui Huang , Qiang Wei , Xiang Li , Jiyan Liu , Pengfei Shen , Ni Chen , Jin Yao , Zhenhua Liu , Hao Zeng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04387500

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 685)

DOI

10.1200/JCO.2023.41.6_suppl.685

Abstract #

685

Poster Bd #

H17

Abstract Disclosures

Similar Posters

First Author: Sonam Ansel

First Author: Michael B. Atkins

First Author: Martin Henner Voss

First Author: David F. McDermott